BridgeBio have substantially improved this course of an innovative therapy for ATTR-CM, employing the investigational drug. Initial trial results suggests promising improvements for individuals diagnosed by a severe illness. The focus represents BridgeBio's focus to treating unmet healthcare demands in this heart disease arena. Attruby: BridgeBio'